Korea Health Industry Development Institute President Soon-Do Cha talks to Scrip how the government agency’s support strategy to the domestic biopharma industry may be changing in line with the industry’s increased globalization move and how he views the country’s policy stance should improve going forward to meet its goal of becoming a strong biohealth nation.

With Hanmi's progress in changing the main indication of its GLP-1 contender efpeglenatide to obesity, Scrip takes an infographic look at what other Korean firms are doing in both this indication and elsewhere in the GLP-1 space. 

Aside from a mixed bag of second-quarter earnings, the latest developments in the Korean pharma industry include Hanmi’s search for new indications for u-turned assets and the approval of Yuhan’s lazertinib as a first-line treatment for NSCLC.

As the global economy remains in a slump, even big pharmas such as Novartis and Pfizer are cutting costs. So how should Korean biopharmas adapt to such an environment and move ahead? Korea Drug Development Fund CEO H. Samuel Muk provides some ideas on how domestic players can survive in this new global reality.